AI English summary of an SEC filing — figures as filed
Agilent Technologies AThe company said net revenue for the quarter ended January 31, 2024 was $1,658 million, down 6% from the same period a year earlier. It said foreign currency movements had a favorable impact of 1 percentage point on revenue growth, and it cited continued customer capital expenditure pressures.
Key points
AI summaryThe company said net revenue for the quarter ended January 31, 2024 was $1,658 million, down 6% from the same period a year earlier. It said foreign currency movements had a favorable impact of 1 percentage point on revenue growth, and it cited continued customer capital expenditure pressures.
Agilent said that in the same quarter, revenue in its life sciences and applied markets segment fell 10% and revenue in its diagnostics and genomics segment fell 6%, while Agilent CrossLab revenue rose 6%. All changes are year over year, and the favorable foreign currency impact was 1 percentage point for each segment respectively.
The company said net income for the quarter was $348 million, roughly flat with $352 million a year earlier, and cash provided by operations rose to $485 million from $296 million in the same period last year.
The company said cash and cash equivalents stood at $1,748 million as of January 31, 2024, and that it paid cash dividends of $0.236 per share, or $69 million in total, during the quarter. It did not repurchase any shares in the same period, and the remaining authorization under the 2023 repurchase program was approximately $1.524 billion.
Key figures
Quarter ended January 31, 2024
- Revenue
- $1.7B
- Operating income
- $384M
- Net income
- $348M
- EPS
- $1.18
- Operating cash flow
- $485M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly revenue $1,658 million, down 6%
The company said net revenue for the quarter ended January 31, 2024 was $1,658 million, down 6% from the same period a year earlier. It said foreign currency movements had a favorable impact of 1 percentage point on revenue growth, and it cited continued customer capital expenditure pressures.
Source · Based on the MD&A text of the filing
Segment revenue: two segments decline, CrossLab rises
Agilent said that in the same quarter, revenue in its life sciences and applied markets segment fell 10% and revenue in its diagnostics and genomics segment fell 6%, while Agilent CrossLab revenue rose 6%. All changes are year over year, and the favorable foreign currency impact was 1 percentage point for each segment respectively.
Source · Based on the MD&A text of the filing
Net income $348 million, operating cash flow $485 million
The company said net income for the quarter was $348 million, roughly flat with $352 million a year earlier, and cash provided by operations rose to $485 million from $296 million in the same period last year.
Source · Based on the MD&A text of the filing
Cash $1,748 million, dividends and buyback authorization balance
The company said cash and cash equivalents stood at $1,748 million as of January 31, 2024, and that it paid cash dividends of $0.236 per share, or $69 million in total, during the quarter. It did not repurchase any shares in the same period, and the remaining authorization under the 2023 repurchase program was approximately $1.524 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…